Literature DB >> 28317798

Nontuberculous mycobacterial species and Mycobacterium tuberculosis complex coinfection in patients with pulmonary tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia.

Ni Made Mertaniasih1, Deby Kusumaningrum1, Eko Budi Koendhori1, Tutik Kusmiati2, Desak Nyoman Surya Suameitria Dewi3.   

Abstract

OBJECTIVE/
BACKGROUND: The aim of this study was to analyze the detection of nontuberculous mycobacterial (NTM) species derived from sputum specimens of pulmonary tuberculosis (TB) suspects. Increasing prevalence and incidence of pulmonary infection by NTM species have widely been reported in several countries with geographical variation.
MATERIALS AND METHODS: Between January 2014 and September 2015, sputum specimens from chronic pulmonary TB suspect patients were analyzed. Laboratory examination of mycobacteria was conducted in the TB laboratory, Department of Clinical Microbiology, Dr. Soetomo Hospital, Surabaya. Detection and identification of mycobacteria were performed by the standard culture method using the BACTEC MGIT 960 system (BD) and Lowenstein-Jensen medium. Identification of positive Mycobacterium tuberculosis complex (MTBC) was based on positive acid-fast bacilli microscopic smear, positive niacin accumulation, and positive TB Ag MPT 64 test results (SD Bioline). If the growth of positive cultures and acid-fast bacilli microscopic smear was positive, but niacin accumulation and TB Ag MPT 64 (SD Bioline) results were negative, then the isolates were categorized as NTM species. MTBC isolates were also tested for their sensitivity toward first-line anti-TB drugs, using isoniazid, rifampin, ethambutol, and streptomycin.
RESULTS: From 2440 sputum specimens of pulmonary TB suspect patients, 459 isolates (18.81%) were detected as MTBC and 141 (5.78%) as NTM species.
CONCLUSION: From the analyzed sputum specimens, 18.81% were detected as MTBC and 5.78% as NTM species. Each pulmonary TB suspect patient needed clinical settings to suspect causative agents of MTBC and/or NTM species; clinicians have to understand the local epidemiological data for the evaluation of causes of lung infection to determine appropriate therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28317798     DOI: 10.4103/2212-5531.201894

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  5 in total

1.  Disseminated tuberculosis with symptoms of decreased consciousness: A rare case in Indonesian male.

Authors:  Alvian Fauzi; Ariani Permatasari
Journal:  Ann Med Surg (Lond)       Date:  2021-12-22

2.  Association between serum PGE2 levels and degree of acid-fast bacilli positivity in sputum of pulmonary tuberculosis patients.

Authors:  Herley Windo Setiawan; Resti Yudhawati; Irmi Syafaah
Journal:  Ann Med Surg (Lond)       Date:  2021-11-03

3.  Tween 80 Improves the Acid-Fast Bacilli Quantification in the Magnetic Nanoparticle-Based Colorimetric Biosensing Assay (NCBA).

Authors:  Cristina Gordillo-Marroquín; Héctor J Sánchez-Pérez; Anaximandro Gómez-Velasco; Miguel Martín; Karina Guillén-Navarro; Janeth Vázquez-Marcelín; Adriana Gómez-Bustamante; Letisia Jonapá-Gómez; Evangelyn C Alocilja
Journal:  Biosensors (Basel)       Date:  2022-01-07

4.  Drug susceptibility profiles and factors associated with non-tuberculous mycobacteria species circulating among patients diagnosed with pulmonary tuberculosis in Tanzania.

Authors:  Togolani Godfrey Maya; Erick Vitus Komba; Gloria Ivy Mensah; Peter Masunga Mbelele; Stella George Mpagama; Sayoki Godfrey Mfinanga; Kennedy Kwasi Addo; Rudovick Reuben Kazwala
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

5.  Characteristic profile of antibody responses to PPD, ESAT-6, and CFP-10 of Mycobacterium tuberculosis in pulmonary tuberculosis suspected cases in Surabaya, Indonesia.

Authors:  Desak Nyoman Surya Suameitria Dewi; Ni Made Mertaniasih; Yuriko Ozeki; Wayan Tunas Artama; Mamiko Niki; Yoshitaka Tateishi; Manabu Ato; Sohkichi Matsumoto
Journal:  Braz J Infect Dis       Date:  2019-08-14       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.